InvestorsHub Logo
Followers 800
Posts 50869
Boards Moderated 2
Alias Born 12/12/2004

Re: stockmania post# 180

Thursday, 11/29/2007 5:53:31 PM

Thursday, November 29, 2007 5:53:31 PM

Post# of 5735
I talked to a Biomoda employee last evening.
They are now up to 8 employees....also they are very excited about 2008.
By next summer they will be very close to marketing their products.

Our plan of operation for the next twelve months is to complete the validation studies for our lung cancer assay, design our diagnostic product, choose our contract manufacturing partner, manufacture our initial batches, register our product with the FDA and then with European authorities for our CE mark, and begin marketing to reference labs in the US and Europe. To that end, we have contracted with Quintiles Consulting for regulatory consulting, TriCore Reference Laboratories for assay preparation, Averion International Corporation for clinical services, and Clinical Research Center of Cape Cod. to provide lung sputum samples. We intend to have initial revenues in the last quarter of 2008. The Company is raising funds from the sale of restricted common stock through a Regulation S Offering and is assessing various offering scenarios.

Our initial product is a diagnostic test for lung cancer that will be performed out of body by using a sputum sample from the patient. Our test does not require any invasive sample taking. The sample will be sent to a clinical lab where the procedure will be performed to determine the presence, or not, of lung cancer or precancerous cells. Our diagnostic test can be used for other cell samples and we intend to create and market products to diagnose and screen for other prevalent cancers such as breast, cervical, bladder, and colorectal. We have determined that our initial markets will be the developed nations of Europe, North America and Japan. This has been determined on the basis of available healthcare delivery and payer infrastructure. Japan is leading the world, and has instituted a nationwide lung cancer-screening program. We also intend to sell our product in additional markets throughout the world such as India, Brazil and South America, Asia and Russia. We will market different product formats based on the region of the world.

To be is to do.(Socrates) To do is to be.(Plato) Do be do be do!!!!!(Sinatra)

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.